Rebuilding the Damaged Heart The Potential of Cytokines and Growth Factors in the Treatment of Ischemic Heart Disease

被引：89

作者：

Beohar, Nirat ^{[1
,2
]}

Rapp, Jonathan ^{[2
,4
]}

Pandya, Sanjay ^{[2
]}

Losordo, Douglas W. ^{[1
,2
,3
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA

[2] Northwestern Univ, Div Cardiol, Chicago, IL 60611 USA

[3] NW Mem Hosp, Bluhm Cardiovasc Inst, Program Cardiovasc Regenerat Med, Chicago, IL 60611 USA

[4] Ochsner Clin Fdn, Dept Cardiol, New Orleans, LA USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2010年 / 56卷 / 16期

基金：

美国国家卫生研究院;

关键词：

angiogenesis; cytokines; heart failure; regenerative medicine; COLONY-STIMULATING FACTOR; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; STEM-CELL MOBILIZATION; ENDOTHELIAL PROGENITOR CELLS; LEFT-VENTRICULAR FUNCTION; PLACEBO-CONTROLLED TRIAL; ANGIOGENIC GENE-THERAPY; DOUBLE-BLIND; GRANULOCYTE-MACROPHAGE;

D O I：

10.1016/j.jacc.2010.05.039

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cytokine therapy promises to provide a noninvasive treatment option for ischemic heart disease. Cytokines are thought to influence angiogenesis directly via effects on endothelial cells or indirectly through progenitor cell-based mechanisms or by activating the expression of other angiogenic agents. Several cytokines mobilize progenitor cells from the bone marrow or are involved in the homing of mobilized cells to ischemic tissue. The recruited cells contribute to myocardial regeneration both as a structural component of the regenerating tissue and by secreting angiogenic or antiapoptotic factors, including cytokines. To date, randomized, controlled clinical trials have not reproduced the efficacy observed in pre-clinical and small-scale clinical investigations. Nevertheless, the list of promising cytokines continues to grow, and combinations of cytokines, with or without concurrent progenitor cell therapy, warrant further investigation. (J Am Coll Cardiol 2010; 56: 1287-97) (C) 2010 by the American College of Cardiology Foundation

引用

页码：1287 / 1297

页数：11

共 137 条

[41] G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes [J].

Harada, M ;

Qin, YJ ;

Takano, H ;

Minamino, T ;

Zou, YZ ;

Toko, H ;

Ohtsuka, M ;

Matsuura, K ;

Sano, M ;

Nishi, J ;

Iwanaga, K ;

Akazawa, H ;

Kunieda, T ;

Zhu, WD ;

Hasegawa, H ;

Kunisada, K ;

Nagai, T ;

Nakaya, H ;

Yamauchi-Takihara, K ;

Komuro, I .

NATURE MEDICINE, 2005, 11 (03) :305-311

[42] Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells [J].

Hattori, K ;

Dias, S ;

Heissig, B ;

Hackett, NR ;

Lyden, D ;

Tateno, M ;

Hicklin, DJ ;

Zhu, ZP ;

Witte, L ;

Crystal, RG ;

Moore, MAS ;

Rafii, S .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (09) :1005-1014

[43]

HATTORI K, 2002, NAT MED, V1, P1

[44] Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia -: Phase II results of the Kuopio Angiogenesis Trial (KAT) [J].

Hedman, M ;

Hartikainen, J ;

Syvänne, M ;

Stjernvall, J ;

Hedman, A ;

Kivelä, A ;

Vanninen, E ;

Mussalo, H ;

Kauppila, E ;

Simula, S ;

Närvänen, O ;

Rantala, A ;

Peuhkurinen, K ;

Nieminen, MS ;

Laakso, M ;

Ylä-Herttuala, S .

CIRCULATION, 2003, 107 (21) :2677-2683

[45] Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization [J].

Heeschen, C ;

Aicher, A ;

Lehmann, R ;

Fichtischerer, S ;

Vasa, M ;

Urbich, C ;

Mildner-Rihm, C ;

Martin, H ;

Zeiher, AM ;

Dimmeler, S .

BLOOD, 2003, 102 (04) :1340-1346

[46] Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand [J].

Heissig, B ;

Hattori, K ;

Dias, S ;

Friedrich, M ;

Ferris, B ;

Hackett, NR ;

Crystal, RG ;

Besmer, P ;

Lyden, D ;

Moore, MAS ;

Werb, Z ;

Rafii, S .

CELL, 2002, 109 (05) :625-637

[47] Vascular endothelial growth factor in ischemia for vascular angiogenesis [J].

Henry, TD ;

Annex, BH ;

McKendall, GR ;

Azrin, MA ;

Lopez, JJ ;

Giordano, FJ ;

Shah, PK ;

Willerson, JT ;

Benza, RL ;

Berman, DS ;

Gibson, CM ;

Bajamonde, A ;

Rundle, AC ;

Fine, J ;

McCluskey, ER .

CIRCULATION, 2003, 107 (10) :1359-1365

[48] Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease [J].

Henry, TD ;

Rocha-Singh, K ;

Isner, JM ;

Kereiakes, DJ ;

Giordano, FJ ;

Simons, M ;

Losordo, DW ;

Hendel, RC ;

Bonow, RO ;

Eppler, SM ;

Zioncheck, TF ;

Holmgren, EB ;

McCluskey, ER .

AMERICAN HEART JOURNAL, 2001, 142 (05) :872-880

[49] Effect of Ad5FGF-4 in patients with angina - An analysis of pooled data from the AGENT-3 and AGENT-4 trials [J].

Henry, Timothy D. ;

Grines, Cindy L. ;

Watkins, Matthew W. ;

Dib, Nabil ;

Barbeau, Gerald ;

Moreadith, Randall ;

Andrasfay, Tony ;

Engler, Robert L. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (11) :1038-1046

[50] Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease [J].

Hill, JM ;

Syed, MA ;

Arai, AE ;

Powell, TM ;

Paul, JD ;

Zalos, G ;

Read, EJ ;

Khuu, HM ;

Leitman, SF ;

Horne, M ;

Csako, G ;

Dunbar, CE ;

Waclawiw, MA ;

Cannon, RO .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (09) :1643-1648

← 1 2 3 4 5 6 7 8 9 10 →